CHOLOVUE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLOVUE is an injectable diagnostic agent developed by Bracco, approved in 1981 for diagnostic imaging purposes. The specific mechanism of action and therapeutic indication are not publicly detailed in available data, but the injectable formulation suggests use in imaging or contrast-based diagnostics. This is a legacy NDA product with over 40 years of market history.
LOE Approaching
LOE-approaching legacy product with low linked job count suggests minimal commercial expansion and potential team consolidation ahead.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHOLOVUE has zero linked job openings, indicating minimal hiring and team activity. Roles on this product are primarily defensive, focused on maintaining market position and managing decline rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on CHOLOVUE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.